drugset / Trial / NCT04696029
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NaSingle-groupOpen-labelTreatment
Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Timeline
- Start
- 2021-03-29
- Primary completion
- 2028-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | 2500 mg/m2 | Oral |